Projects per year
Personal profile
Biography
A graduate of the University of Melbourne in 2003, Dr Teh initially trained at St Vincent's Hospital before undertaking his haematology training at the Alfred Hospital. He received his fellowship with the RACP and RCPA in 2012.
Dr Teh has an interest in acute myeloid leukaemia and completed a PhD in AML at Monash University in 2016.
He is currently a VMO at the Alfred Hospital, and a haematopathologist at Eastern Health.
Research area keywords
- Haematology
- Acute myeloid leukaemia
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
Teh, T.-C. (Primary Chief Investigator (PCI)), Slade, C. (Chief Investigator (CI)), Bird, R. J. (Chief Investigator (CI)), Barnes, S. (Chief Investigator (CI)), Randall, K. L. (Chief Investigator (CI)) & Kennedy, N. (Project Manager)
30/11/21 → 31/12/26
Project: Research
-
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients with Myeloid Malignancies
Teh, T.-C. (Primary Chief Investigator (PCI)) & Kennedy, N. (Project Manager)
5/05/21 → 31/12/26
Project: Research
-
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin Alfa for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naive Subjects who require Red Blood Cell Transfusions.
Teh, T.-C. (Primary Chief Investigator (PCI)), Tiong, I. S. (Primary Chief Investigator (PCI)) & Kennedy, N. (Chief Investigator (CI))
15/07/19 → 3/12/26
Project: Research
-
A Phase 1b, multicenter, open-label platform study of select drug combinations in adult patients with lower risk (very low, low, or intermediate risk) myelodysplastic syndrome
Tiong, I. S. (Primary Chief Investigator (PCI)), Teh, T.-C. (Primary Chief Investigator (PCI)) & Kennedy, N. (Project Manager)
1/04/21 → 31/12/25
Project: Research
-
Leukaemia Foundation Scholarship (Clinical) - Tse-Chieh TEH
Teh, T.-C. (Primary Chief Investigator (PCI))
31/03/11 → 30/03/14
Project: Research
-
Final analysis of the phase 1b Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT)
Chua, C. C., Loo, S., Fong, C. Y., Ting, S. B., Tiong, I. S., Fleming, S., Anstee, N. S., Ivey, A., Ashby, M., Teh, T. C., Reynolds, J., Roberts, A. W. & Wei, A. H., 22 Apr 2025, In: Blood Advances. 9, 8, p. 1827-1835 9 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access7 Link opens in a new tab Citations (Scopus) -
Low-intensity venetoclax-based salvage as a bridge to allogeneic stem cell transplant in patients with acute myeloid leukemia failing conventional intensive chemotherapy
Ashby, M., Fleming, S., Teh, T. C., Tiong, I. S., Inam, S., Curtis, D. J., Patil, S., Vassili, C. & Chua, C. C., Jan 2024, In: Leukemia Research. 136, 4 p., 107429.Research output: Contribution to journal › Letter › Research › peer-review
1 Link opens in a new tab Citation (Scopus) -
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)
Tiong, I. S., Hiwase, D. K., Abro, E., Bajel, A., Palfreyman, E., Beligaswatte, A., Reynolds, J., Anstee, N., Nguyen, T., Loo, S., Chua, C. C., Ashby, M., Wiltshire, K. M., Fleming, S., Fong, C. Y., Teh, T. C., Blombery, P., Dillon, R., Ivey, A. & Wei, A. H., 20 Jun 2024, In: Journal of Clinical Oncology. 42, 18, p. 2161-2173 13 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access29 Link opens in a new tab Citations (Scopus) -
Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic
Tedjaseputra, A., Kuzich, J. A., Thiagarajah, N., Teh, T. C., McClelland, J., Rahman, M., Brook, R., Chua, C. C., Ong, D. M., Tan, S. Y., Filshie, R., Fong, C. Y., Fedele, P., Bajel, A., Shortt, J. & Wei, A. H., 2022, In: Leukemia and Lymphoma. 63, 11, p. 2731–2734 4 p.Research output: Contribution to journal › Letter › Other › peer-review
1 Link opens in a new tab Citation (Scopus) -
Combining BH3-Mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
Moujalled, D. M., Pomilio, G., Ghiurau, C., Ivey, A., Salmon, J., Rijal, S., Macraild, S., Zhang, L., Teh, T. C., Tiong, I. S., Lan, P., Chanrion, M., Claperon, A., Rocchetti, F., Zichi, A., Kraus-Berthier, L., Wang, Y., Halilovic, E., Morris, E. & Colland, F. & 7 others, , 1 Apr 2019, In: Leukemia. 33, a, p. 905-917 13 p.Research output: Contribution to journal › Article › Research › peer-review
Open AccessFile140 Link opens in a new tab Citations (Scopus)